Browse the evidence

Tirzepatide's dual GIP/GLP-1 receptor agonism provides a synergistic mechanism that enhances weight loss and mitigates gastrointestinal side effects compared to selective GLP-1 agonists.

Tirzepatide works differently than semaglutide by activating both GIP and GLP-1 receptors. This dual action may lead to greater fat loss and potentially fewer stomach side effects.

GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).

Tirzepatide is the first FDA-approved medical therapy for OSA, showing significant improvements in sleep apnea severity (AHI) in patients with obesity. This benefit occurs both in patients using CPAP and those not using it. It offers a new treatment option for those struggling with OSA, potentially reducing the burden of the disease.

Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.

Newer 'triple-agonist' weight loss medications target three different hormonal pathways (GLP-1, GIP, and Glucagon) instead of just one. Clinical trials show these can lead to over 20% body weight loss, which is significantly higher than older single-target drugs. These are currently experimental and not yet widely available for general use.

Lixisenatide, high-dose canagliflozin (300 mg/day), empagliflozin, and dapagliflozin are associated with a reduced risk of acute kidney injury compared to control treatments.

If you are taking lixisenatide, high-dose canagliflozin, empagliflozin, or dapagliflozin, you may have a lower risk of acute kidney injury compared to those not on these medications. Continue to follow your doctor's recommendations for kidney function monitoring, as these benefits do not eliminate the need for standard care.

Tirzepatide (10 mg and 15 mg) significantly improves health-related quality of life (HR-QoL) in Japanese adults with obesity disease compared to placebo over 72 weeks.

For Japanese adults with obesity disease, treatment with tirzepatide (10 mg or 15 mg weekly, escalated from 2.5 mg) alongside lifestyle changes significantly improves quality of life, particularly physical function and psychosocial well-being, compared to placebo over 72 weeks.

Denosumab is the most promising pharmacological treatment for osteosarcopenia because it inhibits RANKL in both muscle and bone, leading to increased lean mass, bone mass, grip strength, and reduced fall risk.

Denosumab is currently the most promising drug for treating osteosarcopenia, showing benefits for both muscle and bone. However, it is still under further clinical investigation. It should be considered alongside, not instead of, resistance training and proper nutrition.

Metabolic surgery (VSG/RYGB) alters gut hormone profiles by increasing GLP-1 and PYY while decreasing ghrelin, leading to reduced hunger and improved satiety, which aids in sustained weight loss and glucose control.

Surgery biologically reduces your hunger drive (ghrelin) and increases fullness signals (GLP-1/PYY), making it easier to maintain weight loss compared to dieting alone, which often triggers intense hunger.

Obesity in Type 1 Diabetes is associated with increased cardiometabolic risk, higher insulin requirements, and an enhanced risk of chronic complications compared to normal-weight T1D patients.

Obesity in T1D is not just about weight; it significantly increases the risk of heart disease, kidney issues, and eye problems due to insulin resistance. Managing weight is critical for long-term complication prevention.

Regular aerobic training reduces platelet activation (P-selectin expression) during acute exercise compared to sedentary individuals, despite higher baseline platelet counts in trained subjects.

If you are currently sedentary, your platelets will activate more during intense exercise than if you were trained. This doesn't mean you shouldn't exercise, but it highlights why gradual training is safer. Start with moderate activity to build your cardiovascular system, which will eventually lower your platelet activation response to stress.

Combining a GLP-1 receptor agonist (GLP-1RA) with an SGLT2 inhibitor provides superior glucose control, greater weight loss, and greater reductions in systolic blood pressure compared to either drug alone.

If your blood sugar remains high despite taking metformin, ask your doctor about combining a GLP-1 receptor agonist (like exenatide) with an SGLT2 inhibitor (like dapagliflozin). This combination lowers blood sugar more effectively than either drug alone, helps you lose more weight, and reduces blood pressure.

Higher consumption of trans-18:2 fatty acids (industrial trans fats) is associated with significantly lower heart rate variability (HRV) and higher heart rate in both older and younger adults, indicating autonomic dysfunction and increased arrhythmic risk.

To protect your heart's electrical health and autonomic function, minimize industrial trans fats (trans-18:2) found in fried foods and baked goods. These are linked to reduced heart rate variability and higher heart rates, which are markers of increased cardiac risk. Unlike industrial trans fats, natural trans fats (trans-18:1) found in dairy and meat do not show these negative effects and may even be beneficial for heart rate variability in older adults.

Visceral adiposity, independent of overall BMI, is a significant risk factor for Barrett's esophagus and esophageal adenocarcinoma, mediated by adipokines like leptin and inflammatory cytokines.

Focus on reducing visceral fat through a balanced diet and regular physical activity, even if your overall weight is normal. This can significantly lower your risk of developing Barrett's esophagus and esophageal cancer.

Low-carbohydrate diets improve cardiovascular risk markers (triglycerides, HDL, blood sugar, inflammation) and reduce 10-year ASCVD risk scores, despite potential increases in LDL-C in lean individuals.

If you are on a low-carbohydrate diet, expect improvements in triglycerides, HDL, and blood sugar. If your LDL-C rises, discuss with your provider whether it correlates with other risk factors, as overall cardiovascular risk may still decrease.

Low-dose empagliflozin (2.5-5 mg) as adjunct therapy to hybrid closed-loop systems improves postprandial glycemic control and reduces insulin requirements in adults with type 1 diabetes, though it increases the risk of hypoglycemia and requires management of side effects like increased urination.

If you have Type 1 Diabetes and use a hybrid closed-loop system but still struggle with post-meal spikes or high insulin doses, low-dose empagliflozin (2.5-5mg) can significantly improve your time in range and reduce insulin needs. Be aware that it may cause more frequent urination and a higher risk of post-meal lows, which you can manage by adjusting your pump settings. The benefit of better control often outweighs the inconvenience of taking one extra pill.

A non-carbohydrate counting (non-CC) meal bolus strategy based on preprandial glucose levels, when used with open-source automated insulin delivery (AID), significantly improves time in range (TIR) and reduces glycemic variability compared to manual open-loop modes in adults with Type 1 Diabetes.

If you have Type 1 Diabetes and find carbohydrate counting stressful or error-prone, consider using an open-source automated insulin delivery system (like AndroidAPS) with a simplified bolus strategy. Instead of counting carbs, you calculate your insulin based on your pre-meal glucose level and your average mealtime insulin needs. This approach can significantly improve your time in range and reduce glycemic variability, especially at night, without increasing the risk of hypoglycemia. It is a viable alternative for those who find traditional carb counting burdensome.

Intensive lifestyle interventions (ILI) involving caloric restriction and physical activity cause a significant increase in 25-hydroxyvitamin D [25(OH)D] and suppress parathyroid hormone (PTH) elevation during the period of maximal weight loss in adults with type 2 diabetes.

If you have type 2 diabetes and are losing weight through diet and exercise, expect your Vitamin D levels to rise and your Parathyroid Hormone (PTH) to decrease, especially in the first year. This is a normal and likely beneficial response to weight loss, though it may normalize over time. Monitor your bone health as weight loss can also lead to bone loss.

Intensive glycemic control (target HbA1c < 6%) significantly reduces the development of diabetic peripheral neuropathy (DPN) in patients with Type 1 Diabetes Mellitus (T1DM), but this benefit is not observed in patients with Type 2 Diabetes Mellitus (T2DM).

If you have Type 1 Diabetes, aiming for an HbA1c below 6% is the most effective way to prevent nerve damage. However, if you have Type 2 Diabetes, this aggressive target is not recommended due to lack of neuropathy benefit and increased mortality risk; standard control (7.0-7.9%) is advised instead.

VLCKD improves glycemic profiles (fasting glucose, HbA1c, HOMA-IR) and lipid profiles (triglycerides, total cholesterol) significantly, with some improvements (glycemia, LDL) being similar to other weight loss interventions.

You can expect your blood sugar, insulin resistance, and cholesterol numbers to improve significantly on VLCKD. However, for these specific metabolic markers, the improvement is comparable to what you might get from any other effective weight loss diet, whereas fat loss is specifically better on VLCKD.

Exercise-induced weight loss produces superior improvements in adipokine profiles (increased adiponectin, decreased chemerin), insulin resistance, and systemic inflammation compared to diet-induced weight loss, despite achieving equivalent total body weight reduction.

If your goal is to improve metabolic health, insulin sensitivity, and reduce inflammation, prioritize exercise over strict calorie restriction, even if your total body weight doesn't drop as quickly. Exercise is more effective at targeting fat loss and improving your body's hormonal response to food than dieting alone, provided you maintain a similar energy deficit.

The metabolic benefits of the multifaceted intervention, specifically reductions in fasting insulin and IL-6, occur rapidly, with the greatest decreases observed by week 6 of the 12-week program.

If you start this combined lifestyle program, expect significant improvements in insulin sensitivity and inflammation within the first 6 weeks, even if full fat loss continues until week 12.

Semaglutide significantly improves glycemic control (HbA1c and fasting blood glucose) and systolic blood pressure in overweight or obese adults, with or without type 2 diabetes.

Semaglutide not only helps with weight loss but also significantly improves blood sugar control (HbA1c and fasting glucose) and lowers systolic blood pressure in overweight or obese individuals, offering potential cardiovascular benefits.

Bariatric surgery (specifically Roux-en-Y gastric bypass, sleeve gastrectomy, and biliopancreatic diversion) leads to greater improvements in cardiovascular risk factors (triglycerides, HDL cholesterol, fasting glucose, HbA1c) compared to non-surgical treatment, although blood pressure and total/LDL cholesterol changes are not significantly different.

Bariatric surgery improves key cardiovascular markers like triglycerides, HDL cholesterol, and blood glucose more effectively than non-surgical treatments. However, it does not significantly improve blood pressure or LDL cholesterol compared to lifestyle changes alone. Patients should expect to reduce or stop some medications under medical supervision.

Once-weekly semaglutide (1.0 mg) reduces ad libitum energy intake by approximately 24% through mechanisms of reduced appetite, improved control of eating, and lower preference for high-fat foods, leading to significant body weight loss without compensatory increases in energy expenditure.

Take once-weekly semaglutide (titrated to 1.0 mg over 12 weeks) to reduce hunger, improve control over eating, and lower preference for high-fat foods. This leads to a ~24% reduction in daily calorie intake and significant fat loss, without needing to increase exercise or metabolic rate. Expect mild GI side effects initially.

Weight loss improves insulin sensitivity primarily through the reduction of visceral adipose tissue (VAT), whereas changes in total fat mass or subcutaneous abdominal fat do not significantly predict this improvement.

To improve insulin sensitivity, focus on losing visceral fat through caloric restriction. While total weight loss occurs, the specific reduction of visceral adipose tissue is the primary driver of metabolic improvement, not just the total amount of weight or subcutaneous fat lost. A moderate weight loss (e.g., 15%) is sufficient to significantly improve insulin sensitivity, primarily by targeting visceral stores.